

MEMORANDUM

To: All Wards and Departments, Adult Services, NHS Lothian
 From: Task & Finish Group, Dalteparin Switch, NHS Lothian
 Date: 14 October 2025
 Subject: **An update: Dalteparin to Enoxaparin switch**

An update to previously circulated memo is being issued to highlight a difference in licensed route of administration.

Route of administration

Dalteparin is licensed for administration by subcutaneous injection into the abdominal subcutaneous tissue or into the lateral part of the thigh. Whereas enoxaparin is only licensed for administration into abdominal subcutaneous tissue. Hence, administration into the thigh is an off-label route. However, subcutaneous injection of enoxaparin into the thigh is widely practiced in the UK.

A formulary application form is in progress to add administration into the thigh as an approved alternative route to abdominal tissue in NHS Lothian.

Prescribing- Switching from dalteparin to enoxaparin in Adult patients

For switching patients from dalteparin to enoxaparin, please consult the antithrombotic guide for dosing regimen.

Patients receiving dalteparin	
Thromboprophylaxis Treatment of Venous Thromboembolism	Switch to enoxaparin- refer to antithrombotic guide for dosing. Link to the guideline Thrombosis / Anticoagulation Policies
Complex patients with specialist/haematology input. For example: <ul style="list-style-type: none"> ➤ LMWH dosing adjusted by monitoring of factor Xa level ➤ Bridging dose regimens 	Continue with dalteparin.

Enoxaparin has several branded preparations available. **Inhixa®** is the product of choice in NHS Lothian. **Enoxaparin (Inhixa)** is set as priority item on HEPMA and all strengths of Inhixa will appear at the top when looking to prescribe enoxaparin.

Please contact your clinical pharmacist if you have any questions.